Cumberland Pharmaceuticals Logo

Print Print page   Email Email page   PDF Download PDF    Add to Briefcase
« Previous Release | Next Release »



Cumberland Pharmaceuticals Announces Pricing of Its Initial Public Offering of Common Stock

NASHVILLE, Tenn. (August 10, 2009) - Cumberland Pharmaceuticals Inc. announced today the pricing of its initial public offering of 5,000,000 shares of the Company's common stock at a price to the public of $17.00 per share, raising $85.0 million in gross proceeds before deducting underwriting discounts and commissions as well as offering expenses. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares at the initial public offering price to cover any over-allotments. The common stock is expected to begin trading on the NASDAQ Global Select Market on August 11, 2009, under the trading symbol "CPIX".

Net proceeds to the Company, absent any exercise of the over-allotment option, are expected to be approximately $75.2 million after deducting underwriting discounts and commissions. Cumberland expects to use these proceeds primarily for the pending launch of the Company's Caldolor® product, expansion of the Company's hospital sales force, potential acquisitions, product development, debt repayment and general corporate purposes.

UBS Investment Bank, Jefferies & Company and Wells Fargo Securities are acting as book-running managers for the offering, and Morgan Joseph is acting as co-manager.

A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on August 10, 2009. This offering is being made only by means of a written prospectus. A copy of the final prospectus relating to the offering may be obtained from the prospectus department of UBS Investment Bank, Attn: Prospectus Department, 299 Park Avenue, New York, New York 10171.

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland markets Acetadote® for the treatment of acetaminophen poisoning and Kristalose®, a prescription strength laxative. The Company also recently received FDA approval for Caldolor®, the first injectable treatment for pain and fever available in the United States, and is preparing for the commercial launch of that product. Cumberland is dedicated to providing innovative products which improve quality of care for patients.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

Statements contained in this press release that are not historical facts are "forward looking" statements within the meaning of the federal securities laws. Forward-looking statements, including statements regarding the completion of the proposed initial public offering and any of the terms thereof, are uncertain and subject to a variety of risks that could cause actual results to differ materially from those expected by the Company. Additional information regarding these and other risks can be found in the Company's registration statement relating to the proposed offering.

Corporate Contact
Angela Novak
Corporate Relations
Cumberland Pharmaceuticals
(615) 255-0068
anovak@cumberlandpharma.com

Media Contact
Rebecca Kirkham
Lovell Communications
(615) 297-7766
rebecca@lovell.com



Close window | Back to top